EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Insmed's Enterprise Value is MXN412,511 Mil.
Insmed's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-16,848 Mil. Therefore, Insmed's EV-to-FCF for today is -24.48.
The historical rank and industry rank for Insmed's EV-to-FCF or its related term are showing as below:
MEX:INSM'
s EV-to-FCF Range Over the Past 10 Years
Min: -47.34 Med: -8.39 Max: -3.48
Current: -25.55
During the past 13 years, the highest EV-to-FCF of Insmed was -3.48. The lowest was -47.34. And the median was -8.39.
MEX:INSM's EV-to-FCF is ranked worse than 100% of 331
companies
in the Biotechnology industry
Industry Median: 16.48
vs MEX:INSM: -25.55
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-07-06), Insmed's stock price is MXN3760.00.
Insmed's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-106.007. Therefore, Insmed's PE Ratio (TTM) for today is At Loss.
Insmed (MEX:INSM) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Insmed's share price for today is MXN3760.00.
Insmed's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-106.007.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Insmed EV-to-FCF Related Terms
Insmed EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Insmed's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:INSM vs INCY, BNTX, ROIV: EV-to-FCF Comparison
For the Biotechnology subindustry, Insmed's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insmed EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Insmed's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Insmed's EV-to-FCF falls into.
Insmed's current Enterprise Value is MXN412,511 Mil.
Insmed's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-16,848 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insmed (MEX:INSM) has a EV-to-FCF of -24.48 as of Jul. 06, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Insmed and its competitors. According to the industry distribution chart, Insmed ranks #999999 out of 331 companies in the Biotechnology industry.
Is Insmed's EV-to-FCF too high?
Insmed's current EV-to-FCF is -24.48. Based on the distribution chart, Insmed ranks #999999 out of 331 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Insmed has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Insmed's EV-to-FCF compare to INCY and BNTX?
According to the Biotechnology industry distribution chart, Insmed ranks #999999 out of 331 companies for EV-to-FCF. This places Insmed in the lower half of its industry. The industry median EV-to-FCF is 16.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.48, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Insmed and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insmed's current EV-to-FCF is -24.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Insmed (MEX:INSM) has a current EV-to-FCF of -24.48. The stock's GF Value™ is MXN5,773.42, compared to a current price of MXN3,760.00 — trading 34.9% below its estimated fair value. The current EV-to-FCF is -24.48. Insmed's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Insmed (MEX:INSM), the current EV-to-FCF is -24.48 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insmed (MEX:INSM) Overvalued in 2026?
Based on GuruFocus' analysis, Insmed stock appears to be undervalued.
The current stock price of MXN3,760.00 is trading 34.9% below its estimated GF Value™ of MXN5,773.42.
Key valuation signals for MEX:INSM:
EV-to-FCF: -24.48
GF Value™: MXN5,773.42 vs. price of MXN3,760.00 (34.9% below fair value)
No single metric tells the full story. See the MEX:INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
68GF Score
Get the complete analysis for MEX:INSM
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:INSM has been successfully added to your 
